Canine Atopic Dermatitis Market Size, Share and Trends 2025 to 2034

Canine Atopic Dermatitis Market Size and Forecast 2025 to 2034

The global canine atopic dermatitis market size was calculated at USD 3.21 billion in 2024 and is predicted to increase from USD 3.44 billion in 2025 to approximately USD 6.40 billion by 2034, expanding at a CAGR of 7.14% from 2025 to 2034. The market is growing rapidly because of the growing demand for timely diagnosis and efficient therapies emphasizing non-invasive and targeted therapies. This expansion is anticipated to address the changing requirements of pet owners and veterinary experts.

Canine Atopic Dermatitis Market Key Takeaways

• North America dominated canine atopic dermatitis market with the largest share in 2024.
• Asia Pacific is observed to be the fastest-growing region over the forecast period.
• By product, the glucocorticoids segment dominated the market with the highest market share in 2024.
• By product, the monoclonal antibodies segment is observed to experience a rapid pace of growth during the forecast period.
• By mode of administration, the oral segment led the market in 2024.
• By mode of administration, the injectable segment is seen to experience rapid growth during the forecast period.
• By distribution channel, the retail segment dominated the market in 2024.
• By distribution channel, the e-commerce segment is observed to grow at the fastest rate during the forecast period.

Artificial Intelligence in Canine Treatments

Artificial Intelligence is significantly influencing the canine atopic dermatitis market mainly in areas of diagnosis, treatment enhancement and drug development. Image analysis driven by AI is being investigated to assist veterinarians in diagnosing canine atopic dermatitis with greater accuracy and efficiency. Algorithms in machine learning are capable of recognizing patterns and degrees of severity in images of skin lesions.

AI algorithms are being created to examine extensive datasets of treatment results, assisting veterinarians in customizing treatment plans according to aspects like breed, age and environmental factors. AI is speeding up the drug discovery process for new therapies by examining extensive data and forecasting molecular interactions finding potential new compounds faster and more economically than conventional methods.

• In June 2024, a publication in Veterinary Dermatology presented an AI-driven computer vision model designed to identify canine pododermatitis, a condition frequently associated with atopic dermatitis. The model employs object detection methods to enhance diagnostic precision and efficiency facilitating more effective treatment solutions.

Market Overview

Canine atopic dermatitis is a long-standing, inflammatory skin disease (dogs) brought on by hypersensitivity reactions to environmental allergens such as pollen, dust mites and molds. Canine atopic dermatitis commonly termed as the equivalent of human eczema in canines and characterized by intense pruritus, erythema and secondary skin infection. The demand for canine atopic dermatitis treatment is increasing with growing pet ownership, recognition of dermatological disease and advancements in veterinary medicine. The market comprises products such as antihistamines, corticosteroids, immunosuppressants, biologics and topical treatments.

The market has been rising steadily because of heightened pet health consciousness, the growing incidence of skin diseases among dogs and the development of veterinary medicine. New treatment regimens like biologics and immunotherapy have overhauled treatment for this disorder. The rise in pet keeping and spending on pet healthcare has boosted market growth significantly.

Canine Atopic Dermatitis Market Growth Factors

• Increasing prevalence of Canine Atopic Dermatitis Environmental shifts and increased allergen exposure have resulted in an increased prevalence of skin allergies in dogs increasing the demand for efficient treatment methods.
• Rising Pet Ownership Pet adoption significantly influences the global pet healthcare market fueled by rising ownership and expenditure on treatments especially for canine atopic dermatitis, a condition heightened by the humanization of pets.
• Increased Awareness and Expenditure on Pet Healthcare The increasing recognition of skin issues like canine atopic dermatitis, among veterinarians and pet owners is fueling the need for effective therapies. This heightened consciousness and expenditure on pet healthcare are leading to greater investment in sophisticated diagnostics and treatments for pet health.
• Advancements in Veterinary Healthcare Veterinary dermatology is experiencing notable progress as innovative therapies such as monoclonal antibodies and immunomodulators are transforming treatment methods and offering more effective choices for pet owners. These developments aid in the growth of the market for canine atopic dermatitis management.
• Developing Economies Expansion in developing countries where pet ownership is increasing, signifies a major opportunity for market growth especially for global pharmaceutical and veterinary healthcare firms.

Market Scope

Market Dynamics

Drivers

Increasing Cases due to Environmental Allergens

The canine atopic dermatitis market is driven by the increasing prevalence of canine atopic dermatitis due to environmental allergens in dogs. This expansion is driven by heightened awareness of skin conditions of pet owners and their readiness to spend on advanced veterinary services and treatments. The market services play crucial role in the overall well-being of dogs.

• In September 2024, Elanco Animal Health received approval from the U.S. Food and Drug Administration for Zenrelia, an oral immunosuppressant designed to treat pruritus and atopic dermatitis in dogs that are 12 months old or older. The medication provides superior alleviation of itching and skin lesions in comparison to Apoquel by Zoetis.

Restraint

Higher Cost of Associated Treatments

The elevated expense of treatments especially advanced therapies such as biologics and immunomodulators poses a major limitation in the canine atopic dermatitis market. Medications like Apoquel and cyclosporine are costly and might need prolonged use impacting the growth of the market. The expense of routine veterinary visits, diagnostic tests and ongoing care adds to the overall cost particularly in developing markets where disposable incomes and pet insurance are limited. This might discourage pet owners from obtaining appropriate care or restrict their capacity to afford ongoing management.

Opportunity

Development of Innovative Treatment Strategies

The potential for growth in the canine atopic dermatitis market is found in the development of innovative treatment strategies including immunomodulatory therapies and stem cell treatments. These therapies provide more efficient and durable relief for dogs experiencing canine atopic dermatitis especially those unresponsive to traditional treatments. The use of advanced treatment techniques including biologics, monoclonal antibodies and immunotherapy will overcome the shortcomings of conventional therapies and drive market expansion by improving accessibility and individualized care.

• In August 2024, VetCell Therapeutics collaborated with Western University of Health Sciences to carry out a clinical study investigating mesenchymal stem cells as a potential treatment for canine atopic dermatitis, with the goal of evaluating their effectiveness in providing sustained relief and controlling inflammation.

Product Insights

The glucocorticoids segment dominated the canine atopic dermatitis market with the largest share in 2024. This because glucocorticoids are a commonly used therapy for canine atopic dermatitis because of their strong anti-inflammatory effects, quick results and affordability. They are commonly utilized as the initial treatment for sudden exacerbations of the condition with oral medications such as prednisone, prednisolone and methylprednisolone being especially effective in alleviating symptoms like itching and inflammation.
Topical glucocorticoid sprays are commonly employed for localized skin conditions, delivering focused relief while ensuring minimal absorption into the system. These benefits have established glucocorticoids as a fundamental treatment for canine atopic dermatitis ensuring they are available to many pet owners.

• In June 2021, Cortavance, a topical glucocorticoid aerosol from Virbac serves as a primary therapy for canine atopic dermatitis and includes hydrocortisone aceponate. It offers quick alleviation from inflammation and itchiness, with minimal systemic absorption. The revised claim permits daily use for a maximum of 28 days showcasing the cost-effectiveness, effectiveness and low side-effects of glucocorticoids.

The monoclonal antibodies segment is seen to experience rapid growth in the canine atopic dermatitis market over the forecast period of 2025 to 2034, because of its precise therapeutic method, significant effectiveness and enduring results. Monoclonal antibodies such as lokivetmab, block canine interleukin-31 (IL-31), a cytokine that triggers the itch-scratch cycle in dogs. They offer quick and long-lasting relief from itching with few side effects which makes them favored by vets and pet owners. Their administration every four to eight weeks improves adherence compared to daily oral medications. The growing incidence of canine atopic dermatitis and higher rates of pet adoption contribute to the demand for these innovative treatments.

Mode of Administration Insights

The oral segment dominated the canine atopic dermatitis market with the highest revenue in 2024, because of its affordability, practicality and simple administration. Oral medications such as glucocorticoids and oclacitinib are commonly utilized because they are cost-effective and can be given at home without need of help by veterinarian.

These medications are useful in treating both acute and chronic ailments offering quick alleviation from inflammation and itching. Their adaptability in dosage and capacity to be modified or adjusted render them appropriate for extended management. The cost efficiency and ease of oral administration led to their popularity in treating canine atopic dermatitis.

• In June 2023, Zoetis obtained FDA approval for Apoquel Chewable, a newly formulated product aimed at managing pruritus in dogs that are 12 months old or older. The chewable tablet provides similar effectiveness but with better flavor potentially increasing adherence to medication among pet owners. The revenue increase dermatology portfolio of Zoetis in 2024 is primarily attributed to the success of Apoquel underscoring leadership of the oral segment market due to its convenience and efficacy.

The injectable segment is observed to experience rapid growth in the canine atopic dermatitis market over the forecast period of 2025 to 2034, because of its strong effectiveness and quick onset of action. Injectable treatments especially monoclonal antibodies such as Cytopoint deliver specific relief by countering interleukin-31 (IL-31), a cytokine that causes itching in dogs.

These treatments deliver enduring results with one injection alleviating symptoms for 4 to 8 weeks minimizing the necessity for regular treatments and enhancing adherence. Veterinarians frequently recommend a mix of oral and injectable treatments for the best outcomes. The existence of a broad product pipeline and continuous research into injectable therapies drives the growth of this market.

Distribution Channel Insights

The retail segment dominated the canine atopic dermatitis market with the highest share in 2024, owing to its wide range of product offerings and the rise of retail pharmacy chains. Pharmacies provide a diverse assortment of items including products that veterinary clinics may lack and the implementation of digital systems has minimized prescription mistakes enhancing customer confidence and contentment. Veterinarians frequently depend on retail pharmacies to fulfill prescriptions for medications that are not available in specialized clinics thereby boosting market share of the retail segment. The ease, availability and wider variety of treatments render retail pharmacies a favored option for pet owners. The incorporation of digital systems in retail pharmacies has also improved the dependability and effectiveness of this distribution channel.

• In May 2024, Petco Health and Wellness Company collaborated with veterinary clinics to provide atopic dermatitis treatments straight to pet owners enhancing access to medications while merging retail convenience with veterinary knowledge. The program featured improved digital prescription services.

The e-commerce segment is experiencing rapid growth in the canine atopic dermatitis market over the forecast period, because of its convenience, availability and affordability. Digital platforms provide comprehensive descriptions, special offers and subscription plans simplifying the process for pet owners to choose appropriate treatments. The rising popularity of online shopping along with round the clock access and home delivery choices has enhanced the growth of this segment. The COVID-19 pandemic has intensified this change as pet owners look for safer and more convenient methods to buy medications. This renders online shopping a desirable and economical choice for pet owners looking for dermatological care.

Regional Insights

North American dominated the canine atopic dermatitis market with the highest share in 2024, because of elevated pet ownership levels, a sophisticated veterinary healthcare system, and significant funding in research and development by leading pharmaceutical firms. The area gains advantages from heightened consciousness among pet owners, growing disposable income and extensive access to new treatment alternatives.
Large pharmaceutical firms are significantly pouring resources into creating new medications which is propelling market expansion. Major industry stakeholders such as Zoetis and current clinical trials enhance the supremacy of market in North America.

• In September 2024, the FDA granted approval to Zenrelia by Elanco Animal Health, an oral immunosuppressant for canine atopic dermatitis showing better effectiveness and reduced costs compared to current therapies such as Apoquel.
• In January 2023, Royal Canin North America introduced SKINTOPIC, a specialized diet shown to effectively manage atopic dermatitis and decrease dependency on medications. These advancements illustrate dedication of North America to enhancing veterinary care via partnerships and investments in research and development.

U.S. Trends in the Canine Atopic Dermatitis Market

The U.S market for canine atopic dermatitis is led by its significant population of pet dogs. The demand for veterinary care services is fueled by the sophisticated healthcare infrastructure of nation, significant spending on pet healthcare and the presence of key companies such as Zoetis and Elanco. The regulatory assistance from the FDA aids in the approval and introduction of new veterinary medicines boosting the growth potential of the market. The substantial disposable income of pet owners, ongoing research and development initiatives and FDA-approved regulatory framework of U.S bolster its leading position in the global market

Asia Pacific Canine Atopic Dermatitis Market Trends

Asia Pacific is observed to be the fastest-growing region over the forecast period in the canine atopic dermatitis market2, because of increasing pet ownership, higher disposable incomes and enhanced veterinary healthcare facilities. Nations such as China, India and Japan are embracing pets as companions leading to a rise in demand for sophisticated pet care services such as therapies for atopic dermatitis. 

The increasing consciousness about pet health in the region and the rising influence of global pharmaceutical firms help drive its swift expansion. The continuous developments in healthcare infrastructure of region especially in veterinary services, have made specialized treatments more available and increasing awareness among pet owners regarding skin conditions in pets has also heightened the need for effective treatment solutions.

• In January 2020, Boragen collaborated with a leading global animal health firm to create advanced treatments for canine atopic dermatitis targeting the increasing incidence of the condition in the Asia Pacific area.

India Canine Atopic Dermatitis Market Trends

India is witnessing swift expansion in the canine atopic dermatitis market driven by increasing pet ownership, higher disposable incomes and heightened awareness of pet healthcare. Firms such as Indian Immunologists Limited and Intas Pharmaceuticals Ltd. are allocating resources toward research and development to produce cost-effective options for the budget-conscious market. Innovations in veterinary dermatology, including monoclonal antibodies offer effective and safer treatment alternatives for canine atopic dermatitis.

China Canine Atopic Dermatitis Market Trends

The canine atopic dermatitis market in china is expanding rapidly because of its significant dog population, enhanced veterinary services and increased awareness of pet health. Urban growth and increased incomes enhance pet ownership and the need for superior care. Funding for antimicrobial reduction initiatives and global partnerships such as those with Emergency Centre for Transboundary Animal Diseases, improves capacity of China to handle animal health bolstering its role in the canine atopic dermatitis market.

Latin America Canine Atopic Dermatitis Market Trends

Latin America is emerging as a notable region in the canine atopic dermatitis market due to its large pet dog population and growing awareness about pet healthcare. Key occurrences such as the 6th Latin American Veterinary Dermatology Congress and the activities of the Latin American Society of Veterinary Dermatology showcase the dedication of region to advancements in dermatology.

Due to a significant number of dogs particularly in Brazil and Argentina the need for veterinary services is increasing. Improved veterinary facilities, increasing disposable incomes and collaborations with international pharmaceutical firms seek to enhance access to sophisticated treatments reinforcing role of Latin America as a growing market for canine atopic dermatitis therapies.

Canine Atopic Dermatitis Market Companies

• Zoetis Inc.
• Elanco Animal Health
• Bayer Animal Health
• Boehringer Ingelheim
• Virbac
• Vetoquinol
• Ceva Animal Health
• Dechra Pharmaceuticals
• Merial 
• Merck Animal Health

Leaders’ Announcements

• In June 2024, OKAVA Pharmaceuticals announced encouraging outcomes from a pilot study on their modified-release mycophenolate formulation, OKV-1001 demonstrating notable enhancement in dogs suffering from moderate-to-severe atopic dermatitis that did not respond to standard treatments.
• In January 2024, Gallant Therapeutics secured USD 15 million in Series A funding for regenerative medicine encompassing stem cell treatments for veterinary uses. Indian firms are increasing research funding in novel therapies and expanding collaborations to enhance the growth of the canine atopic dermatitis market.
• In March 2024, Loyal finalized its Series B funding round, securing USD 45 million to create the first FDA-sanctioned dog lifespan extension medication increasing its total funding to more than USD 125 million since 2019.

Recent Developments

• In January 2024, Chewy introduced its ‘Connect with a Vet’ service providing telehealth consultations and product suggestions for pet care including solutions for canine atopic dermatitis. This advancement showcases the changing dynamics of e-commerce platforms.
• In January 2025, the LEO Pharma Partnership, a joint effort between Gilead Sciences and LEO Pharma of Denmark intends to create initiatives focused on inflammatory diseases such as atopic dermatitis, featuring an initial payment of USD 250 million from Gilead. The collaboration seeks to investigate the STAT6 pathway for oral therapy.

Segments covered in report

By Product

• Glucocorticoids
• Antihistamines
• Immunosuppressants
• Monoclonal Antibodies 
• Others

By Mode of administration

• Topical
• Oral
• Injectable

By Distribution Channel

• Veterinary Hospitals/Clinics
• Retail
• E-commerce

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa